Skip to main content

Knight Therapeutics Inc(GUD-T)
TSX

Today's Change
Real-Time Last Update
Day Low7.35
Day High7.58
Open:7.58
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Knight Therapeutics Inc. ranks on The Globe and Mail’s second annual Canada’s Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity
Knight Amends Normal Course Issuer Bid
Stocks in play: Knight Therapeutics Inc.
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
Stocks in play: Knight Therapeutics Inc.
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call
Upcoming Meeting Dates - March 2, 2026
Stocks in play: Knight Therapeutics Inc.
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
Stocks in play: Knight Therapeutics Inc.
Knight Therapeutics Reports Third Quarter 2025 Results
Knight Announces Closing of US$100 Million Revolving Credit Facility
Knight Therapeutics Announces Launch of JORNAY PM™ in Canada
Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies
Knight Announces Normal Course Issuer Bid
Knight Therapeutics Reports Second Quarter 2025 Results
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call
Stocks in play: Knight Therapeutics Inc.
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
Stocks in play: Knight Therapeutics Inc.
Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin
Knight Closes US$50 Million Revolving Credit Facility with NBC

Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.